Cargando…
Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
Several molecular-targeted agents have been tested as first- or second-line therapies for hepatocellular carcinoma (HCC) but failed to improve clinical outcomes; sorafenib has been the only approved systemic agent for treating HCC for almost 10 years. Regorafenib resulted in a significant improvemen...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Liver Cancer Association
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035683/ https://www.ncbi.nlm.nih.gov/pubmed/37383078 http://dx.doi.org/10.17998/jlc.2021.09.23 |